BriaCell Therapeutics Corp. (BCTX) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in West Vancouver, BC, Canada. The current CEO is William V. Williams.
BCTX has IPO date of 2012-03-14, 16 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $8.7M.
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
